HC Wainwright Has Optimistic Outlook of VRCA FY2028 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Stock analysts at HC Wainwright raised their FY2028 earnings estimates for shares of Verrica Pharmaceuticals in a research note issued on Tuesday, April 8th. HC Wainwright analyst O. Livnat now expects that the company will earn $0.11 per share for the year, up from their prior estimate of $0.06. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ FY2029 earnings at $0.18 EPS.

Separately, Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Verrica Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.50.

Verrica Pharmaceuticals Stock Down 10.2 %

Shares of NASDAQ:VRCA opened at $0.58 on Wednesday. The company has a market cap of $53.18 million, a P/E ratio of -0.32 and a beta of 1.68. The business has a fifty day simple moving average of $0.61 and a 200-day simple moving average of $0.89. Verrica Pharmaceuticals has a 52 week low of $0.38 and a 52 week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of VRCA. Invesco Ltd. purchased a new stake in shares of Verrica Pharmaceuticals during the 4th quarter valued at about $32,000. Barclays PLC grew its position in Verrica Pharmaceuticals by 404.6% in the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after acquiring an additional 25,130 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Verrica Pharmaceuticals during the third quarter valued at approximately $87,000. Verition Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the third quarter worth $89,000. Finally, Jane Street Group LLC boosted its stake in shares of Verrica Pharmaceuticals by 106.5% in the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after purchasing an additional 36,028 shares during the period. 42.45% of the stock is owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.